← Back to patent-cliff list
CAS 1616367-19-1
1-((R)-(((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)amino)(phenyl)methyl)naphthalen-2-ol
Codes：APER-015
Application context (from source-drug indications)
斑块银屑病阿普米司特白塞病综合征阿普米司特口腔溃疡阿普米司特银屑病阿普米司特银屑病关节炎阿普米司特
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 阿普米司特Apremilast | Tier B — Position early | 2028 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3-ethoxy-4-methoxybenzaldehyde→N-(1,3-dioxo-1,3-dihydroisobenzofuran-4-yl)acetamide→(R)-1-(amino(phenyl)methyl)naphthalen-2-ol→(1R,3S)-3-(3-ethoxy-4-methoxyphenyl)-1-phenyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazine→lithium (methylsulfonyl)methanide→1-((R)-(((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)amino)(phenyl)methyl)naphthalen-2-ol→(S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.